(All fields required)
Please enter a valid email.
Please enter your name.
David I. Bernstein, MD, MA Director, Gamble Program and VTEU 513-636-7625 email@example.com
Director, Gamble Program and VTEU
Professor, UC Department of Pediatrics
Rotavirus; herpes simplex virus; cytomegalovirus; preclinical and clinical evaluations of vaccine; immune response to herpes virus
Evaluation of vaccines and antivirals for herpes and rotovirus; development of improved adjuvants and delivery systems for vaccines; treatment and prevention of influenza, norovirus and parvovirus infections
Dr. Bernstein received his MA degree in microbiology and his MD degree from SUNY at Buffalo. His pediatric training was undertaken at USC and the New England Medical Center. This was followed by an ID fellowship at UCLA.
During his fellowship he became interested in herpes viruses and vaccines. Upon arrival at Cincinnati Children’s Hospital Medical Center he began his work investigating the immunobiology of genital herpes infections. At this time he also became interested in rotavirus and along with his colleague Dr. Richard Ward he investigated the immune responses that provide protection.
This work led to the development of a live attenuated human rotavirus vaccine initially named 89-12. The 89-12 vaccine was further modified and became the GlaxoSmithKline rotavirus vaccine, Rotarix, currently available in over 100 countries including the USA and EU. Dr. Bernstein is currently evaluating vaccines for CMV, HSV, influenza, avian influenza, RSV, norovirus and parvovirus. Dr. Bernstein has published over 200 manuscripts and book chapters on infectious diseases, vaccines and antivirals. Dr. Bernstein is currently the Albert Sabin Professor of pediatrics and director of the Division of Infectious Diseases at Cincinnati Children’s and directs one of eight NIH funded Vaccine Evaluation Units.
MA: Microbiology, State University of New York at Buffalo, Buffalo, NY, 1973.MD: State University of New York at Buffalo School of Medicine, Buffalo, NY, 1977.
Residency: Pediatrics, University of Southern California Medical Center, Los Angeles, CA; Tufts University School of Medicine, Boston, MA.
Fellowship: Pediatric Infectious Disease, University of California, Los Angeles, CA.
Certification: American Board of Medical Examiners, 1978; American Board of Pediatrics, 1981; Pediatrics, 1982.
Staat MA, Rice MA, Donauer S, Payne DC, Bresee JS, Mast TC, Curns AT, Cortese MM, Connelly B, McNeal M, Ward RL, Bernstein DI, Parashar UD, Salisbury S. Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J. 2010 Dec;29(12):1083-6.
Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV Vaccine Dosing Intervals and Factors Associated With Completion of 3 Doses. Pediatrics. 2010 Dec 13.
Bernstein DI, Epstein T, Murphy-Berendts K, Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol. 2010 Jun;104(6):530-5. Sublett JW, Bernstein DI. Occupational rhinitis. Curr Allergy Asthma Rep. 2010 Mar;10(2):99-104. Bernstein DI. The changing epidemiology of rotavirus gastroenteritis. Introduction. Pediatr Infect Dis J. 2009 Mar;28(3 Suppl):S49. Bernstein DI, Cardin RD, Bravo FJ, Strasser JE, Farley N, Chalk C, Lay M, Fairman J. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol. 2009 May;16(5):699-705. Yee EL, Staat MA, Azimi P, Bernstein DI, Ward RL, Schubert C, Matson DO, Turcios-Ruiz RM, Parashar U, Widdowson MA, Glass RI. Burden of rotavirus disease among children visiting pediatric emergency departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000. Pediatrics. 2008 Nov;122(5):971-7. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008 Mar 1;197(5):667-75.
Bravo FJ, Cardin RD, Bernstein DI. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 2007;76:104-110. Kahn JA, Rosenthal SL, Tissot AM, Bernstein DI, Wetzel C, Zimet GD. Factors influencing pediatricians’ intention to recommend human papillomavirus vaccines. Ambul Pediatr. 2007;7:367-373.
Vaccine and Treatment Evaluation Units (VTEUs): Evaluation of Control Measures Against Diseases Other Than AIDS. Principal Investigator. 2007 - 2014. #NO1-AI-80006.
Rebecca C. Brady, MD Director, Adult Clinical Services 513-636-4578 firstname.lastname@example.org
Director, Adult Clinical Services
Associate Professor, UC Department of Pediatrics
Adult and pediatric infectious disease
MD: University of Kentucky, Lexington, KY, 1988.
Residency: Internal Medicine/Pediatrics, University of Louisville, Louisville, KY.
Fellowships: Pediatric Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio; Adult Infectious Diseases, University of Cincinnati, Cincinnati, OH.
Certifications: Pediatrics, 1992, recertified 1999; Internal Medicine, 1993; Pediatric Infectious Diseases, 1997; Adult Infectious Diseases, 1997.
Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine. 2010 Dec 6;28(52):8258-67. Brady RC. Influenza. Adolesc Med State Art Rev. 2010 Aug;21(2):236-50, viii. Subbramanian RA, Basha S, Brady RC, Hazenfeld S, Shata MT, Bernstein DI. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum Immunol. 2010 Oct;71(10):957-63. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13;27(37):5091-5.
de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine.2006; 24:914-20.
Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay M, Wolff M, She D, Cox MMJ. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. Journal of Infectious Diseases. 2006; 193:1223-8.
Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Journal of the American Medical Association. 2007; 297:1577-82.
Couch RC, Winokur P, Brady RC, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, He F, Nino D, Capellan J, Ruben FL. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007; 25:7656-63.
Rhonda Cardin, PhD 513-636-2420 email@example.com
The research focus of the Cardin lab is to understand the virus-host interactions that are important for CMV pathogenesis and immunological control of long term latent CMV infection. CMV encodes viral homologs to host proteins (such as IL-10, TNF, chemokine receptors) that interfere with the host immune response by immune evasion or by mimicry. Understanding the advantages provided by 'hijacking' of host proteins by CMV will lead to the development of effective vaccine strategies.
Beverly L. Connelly, MD Director, Infection Control Program 513-636-8492 firstname.lastname@example.org
Director, Infection Control Program
MD: Medical College of Georgia, Augusta, Ga., 1979.
Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, Ohio, 1979-1982.
Fellowship: Pediatric Infectious Disease, Children's Hospital Medical Center, Cincinnati, Ohio, 1983-1986.
Certification: Pediatrics, 1984; Pediatric Infectious Diseases, 1994, recertified, 2000.
Lara A. Danziger-Isakov, MD, MPH Director, Transplant ID 513-636-4578 email@example.com
Director, Transplant ID
Transplant infectious diseases
Dr. Danziger-Isakov began her research career investigating cytomegalovirus in pediatric lung transplant recipients. After completing fellowship she led an international epidemiological study of pediatric lung transplant recipients including 14 international sites from North America and Europe to publish seminal manuscripts on fungal and viral infections through the International Pediatric Lung Transplant Collaborative. While at the Cleveland Clinic she performed an innovative investigation evaluating alloreactive cellular and humoral responses to influenza vaccine in transplant recipients. She is the protocol chair for two NIH-funded pediatric transplant studies in the Clinical Trials in Organ Transplantation in Pediatrics (CTOT-C) entitled "Viral Triggers of Alloimmunity and Autoimmunity in Pediatric Lung Transplantation (CTOTC-03)" and "Perceived Barriers to Patient Adherence after Pediatric Solid Organ Transplantation (CTOTC-05)" with principal investigator Stuart Sweet at Washington University.
Dr. Danziger-Isakov is a member of several international organizations, with guest lectureships throughout the North America and Europe. She has been recognized with the Clinical Science Career Development Award from the American Society of Transplantation in 2012, has been elected as co-editor for the American Society of Transplantation’s 3rd Edition of the Infectious Diseases Guidelines, and served as Infectious Disease Council Chair for the International Society of Heart and Lung Transplantation.
MD: Case Western Reserve University, Cleveland, OH, 1997.
MPH: Saint Louis University, St. Louis, MO, 2004.
Residency: Pediatrics, Cleveland Clinic Foundation, Cleveland, OH, 1997-2000.
Fellowship: Pediatric Infectious Diseases, St. Louis Children’s Hospital, Washington Univeristy, St. Louis, MO, 2000-2003.
Certification: Pediatrics, 2000; Pediatric Infectious Diseases, 2003.
Danziger-Isakov LA, Sweet S, DelaMorena M, Mendeloff E, Huddleston CB, DeBaun MR. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. The Pediatr Infectious Disease Journal. 2005; 24(4):324-330.
Spivey JF, Singleton D, Sweet S, Storch GA, Hayashi RJ, Huddleston CB, Danziger-Isakov LA. Prolonged Prophylaxis Against Cytomegalovirus (CMV) With Ganciclovir To Diminish CMV Viremia in Pediatric Lung Transplant Recipients: A Phase II Pilot Study. Pediatric Transplantation. 2007;11(3):312-8.
Danziger-Isakov LA, Worley S, Arrigain S,Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB, Michaels MG, Michelson P, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet S, Faro A. Increased Mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant. 2008; 27(6): 655-661.
Danziger-Isakov LA, Worley S, Michaels MG, Arrigain S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet S, Faro A. The risk, prevention & outcome of cytomegalovirus after pediatric lung transplantation. Transplantation. 2009 May 27;87(10):1541-8.
Liu M, Worley S, Arrigain S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB, Michelson P, Mogayzel PJ, Parakininkas D, Visner G, Sweet S, Faro A, Michaels M, Danziger-Isakov LA. Respiratory Viral Infections within one year after Pediatric Lung Transplant. Transpl Infect Dis. 2009 Aug;11(4):304-12.
Ranganathan K, Worley S, Michaels MG, Arrigan S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB Jr, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet SC, Faro A, Danziger-Isakov L. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J Heart Lung Transplant. 2009 Oct;28(10):1050-6.
Danziger-Isakov LA, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M, Sawinski D, Augustine JJ, Hricik DE, Fairchild R, Heeger PS, Poggio ED. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation, 2010 Apr 15;89(7):838-44.
Cherkassky L, Lanning M, Lalli PN, Czerr J, Siegel H, Danziger-Isakov L, Srinivas T, Valujskikh A, Shoskes DA, Baldwin W, Fairchild RL, Poggio ED. Evaluation of Alloreactivity in Kidney Transplant Recipients Treated with Antithymocyte Globulin Versus IL-2 Receptor Blocker. Am J Transplant. 2011 Jul;11(7):1388-1396.
Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B Immunity and Response to Booster Vaccination in Children With Inflammatory Bowel Disease Treated With Infliximab. Am J Gastroenterol. 2011 Aug 30.
Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012 Aug;31(8):839-44.
Michelle P. Dickey, MS, CFNP, CPNP, CCRC Nurse Practitioner firstname.lastname@example.org
Field Service Instructor, Division of Infectious Diseases
Instructor, UC Department of Pediatrics
Robert W. Frenck Jr., MD Interim Director, Division of Infectious Diseases 513-803-3164 email@example.com
Interim Director, Division of Infectious Diseases
Medical Director, Division of Infectious Diseases
Vaccine research; enteric diseases; travel medicine
Dr. Frenck Jr., MD, can also be reached by this additional phone number: 513-636-7839.
Robert W. Frenck Jr., MD, received his undergraduate degree from the University of California at San Diego in 1977 followed by his doctor of medicine degree from the University of Texas Health Science Center at Houston in 1981. He trained at the National Naval Medical Center in Bethesda, Maryland, completing his pediatric residency in 1984. After three years as a general pediatrician at the US Naval Hospital, Japan, he entered pediatric infectious disease fellowship training at the University of Texas Health Science Center at Houston, which he completed in 1990. Dr. Frenck is board-certified in both pediatrics and infectious diseases.
Dr. Frenck's research interests include therapeutic and vaccine clinical trials with special interest in enteric diseases. After completing a 25-year career in the Navy, Dr. Frenck joined the UCLA Center for Vaccine Research in 2004 and served until 2006 as director of the Center and a Professor of Pediatrics at UCLA School of Medicine. Dr. Frenck has been active in the American Academy of Pediatrics and currently serves on the Red Book Committee. He is an acknowledged authority in infectious diseases and has authored over 60 articles and book chapters on various aspects of this subject.
Riddle MS, Rockabrand DM, Schlett C, Monteville MR, Frenck RW, Romine M, Ahmed SF, Sanders JW. A prospective study of acute diarrhea in a cohort of United States military personnel on deployment to the multinational force and observers, Sinai, Egypt. Am J Trop Med Hyg. 2011 Jan;84(1):59-64.
Schlaudecker EP, Frenck RW Jr. Adolescent pneumonia. Adolesc Med State Art Rev. 2010 Aug;21(2):202-19, vii-viii. Review.
Braverman PK, Frenck RW Jr, Holland-Hall C. Infectious diseases and immunizations. Preface. Adolesc Med State Art Rev. 2010 Aug;21(2):xii. No abstract available.
Matson DO, Abdel-Messih IA, Schlett CD, Bok K, Wienkopff T, Wierzba TF, Sanders JW, Frenck RW Jr. Rotavirus genotypes among hospitalized children in Egypt, 2000-2002. J Infect Dis. 2010 Sep 1;202 Suppl:S263-5.
Frenck RW Jr, Seward JF. Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken). 2010 Jul;62(7):903-6. No abstract available.
Mansour AM, Nakhla II, Sultan YA, Frenck RW Jr. Brucella meningitis: first reported case in Egypt. East Mediterr Health J. 2009 Jul-Aug;15(4):1040-4. No abstract available.
Porter CK, Riddle MS, Tribble DR, Putnam SD, Rockabrand DM, Frenck RW, Rozmajzl P, Kilbane E, Fox A, Ruck R, Lim M, Johnston J, Murphy E, Sanders JW. The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. Diagn Microbiol Infect Dis. 2010 Mar;66(3):241-7.
Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 Jan;105(1):148-54.
Frenck RW, Fathy H, Sherif M, Mohran Z, El Mohammedy, Francis HW, Rockabrand D, Mounir BI, Rozmajzl P, Frierson H. Sensitivity and Specificity of Various Tests for the Diagnosis of H. pylori in Egyptian Children. Pediatrics; 2006;118:e1195-1202.
Monteville MR, Riddle MS, Baht U, Putnam SD, Frenck RW, Brooks K, Moustafa M, Bland J, Sanders JW. Incidence, Etiology and Impact of Diarrhea Among Deployed US Military Personnel in Support of Operation Iraqi Freedom and Operation Enduring Freedom. Am Soc Trop Med Hyg; 2006;75:762-7.
David B. Haslam, MD Director, Antimicrobial Stewardship Program 513-803-1170 firstname.lastname@example.org
Director, Antimicrobial Stewardship Program
Clinical Director, Division of Infectious Diseases
Pediatric infectious diseases; host-microbial interactions; innate immunity
MD: University of Calgary, Calgary, Alberta, 1987.
Rotating Internship: McGill University, Montreal, Quebec, 1988.
Residency: University of Ottawa, Ottawa, Quebec, 1991.
Fellowship: Washington University School of Medicine, St. Louis, MO, 2005.
Certification: Pediatric Infectious Diseases, 1997.
El Feghaly R, Stauber J, Tarr PI, Haslam DB. Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr. 2013 Dec;163(6):1697-1704.
El Feghaly R, Stauber J, Tarr PI, Haslam DB. Viral co-infections are common and are associated with higher bacterial burden in children diagnosed with Clostridium difficile colitis. J Pediatr Gastroenterol Nutr. 2013 Dec;57(6):813-6.
El Feghaly R, Stauber J, Deych E, Gonzales C, Tarr PI, Haslam DB. Markers of intestinal Inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis. 2013;56(12):1713-21.
Bobo, LD, El Feghaly R, Chen YS, Dubberke ER, Han Z, Baker A, Li J, Burnham CA, Haslam DB. MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation. Infect Immun. 2013;81(3):713-722.
Chumbler NM, Farrow MA, Lapierre L, Franklin J, Haslam DB, Goldenring J, Lacey B. Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. Plos Pathogens. 2012;8(12):1-12.
Saenz JB, Li J, Haslam DB. The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response. Cell Microbiol. 2010;12:516-29.
Saenz JB, Sun, W, Chang, JW, Li, J, Bursulaya, B., Gray, NS, Haslam, DB. Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nature Chem Biol.2009;5(3):157-65.
Margaret K. Hostetter, MD BK Rachford Professor and Chair, Department of Pediatrics 513-636-4509 email@example.com
BK Rachford Professor and Chair, Department of Pediatrics
Bacterial and fungal infections; medical evaluation of internationally adopted children
Nancy M. Hutchinson, RN, MSN, CIC Nurse Epidemiologist, Infection Control Program 513-636-8492 firstname.lastname@example.org
Nurse Epidemiologist, Infection Control Program
Field Service Instructor, UC Department of Pediatrics
RN: Christ Hospital School of Nursing, 1967.
MSN: University of Cincinnati, 1992.
Certification: Infection Control Practitioner, CIC, 1995, 2000, 2005.
Xi Jason Jiang, PhD 513-636-0119 email@example.com
Infectious diseases; viral gastroenteritis
Morrow AL, Meinzen-Derr J, Huang P, Schibler KR, Cahill T, Keddache M, Kallapur SG, Newburg DS, Tabangin M, Warner BB, Jiang X. Fucosyltransferase 2 Non-Secretor and Low Secretor Status Predicts Severe Outcomes in Premature Infants. J Pediatr. 2011 Jan 20.
Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology. 2011 Feb 20;410(2):345-52.
Tan M, Huang P, Xia M, Fang PA, Zhong W, McNeal M, Wei C, Jiang W, Jiang X. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol. 2011 Jan;85(2):753-64.
Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog. 2010 Aug 26;6(8). pii: e1000983. Review.
Farkas T, Dufour J, Jiang X, Sestak K. Detection of norovirus-, sapovirus- and rhesus enteric calicivirus-specific antibodies in captive juvenile macaques. J Gen Virol. 2010 Mar;91(Pt 3):734-8.
Tan M, Xia M, Chen Y, Bu W, Hegde RS, Meller J, Li X, Jiang X. Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS One. 2009;4(4):e5058.
Huang P, Morrow AL, Jiang X. The carbohydrate moiety and high molecular weight carrier of histo-blood group antigens are both required for norovirus-receptor recognition. Glycoconj J. 2009 Nov;26(8):1085-96.
Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X. Noroviral P particle: structure, function and applications in virus-host interaction. Virology. 2008 Dec 5;382(1):115-23.
Wei C, Farkas T, Sestak K, Jiang X. Recovery of infectious virus by transfection of in vitro-generated RNA from Tulane calicivirus cDNA. J Virol. 2008 Nov;82(22):11429-36.
Tan M, Xia M, Cao S, Huang P, Farkas T, Meller J, Hegde RS, Li X, Rao Z, Jiang X. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology. 2008 Sep 30;379(2):324-34.
Nancy M. Sawtell, PhD 513-636-7880 firstname.lastname@example.org
Molecular mechanisms of herpes virus latency and reactivation; viral persistence; pathogenesis; animal models of disease
Visit the Sawtell Lab.
BA: Chemistry, Case Western Reserve University, 1975.
PhD: Pathology and Immunology, University of Cincinnati Medical College, Cincinnati, OH, 1986.
Farley N, Bernstein DI, Bravo FJ, Earwood J, Sawtell N, Cardin RD. Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy. Antiviral Res. 2010 May;86(2):188-95. Thompson RL, Preston CM, Sawtell NM. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog. 2009 Mar;5(3):e1000352. Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH, Kambara H, Chiocca EA, Cripe TP. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther. 2008 May;16(5):879-85. Thompson RL, Sawtell NM. Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo. J Virol. 2006 Nov;80(22):10919-30.
Sawtell NM, Thompson RL, Haas RL. Herpes simplex virus DNA synthesis is not a decisive regulatory event in the initiation of lytic viral protein expression in neurons in vivo during primary infection or reactivation from latency. J Virol. 2006 Jan;80(1):38-50. Sawtell NM. Detection and quantification of the rare latently infected cell undergoing herpes simplex virus transcriptional activation in the nervous system in vivo. Methods Mol Biol. 2005;292:57-72.
Sawtell NM, Thompson RL. Comparison of herpes simplex virus reactivation in ganglia in vivo and in explants demonstrates quantitative and qualitative differences. J Virol. 2004 Jul;78(14):7784-94.
Thompson RL, Shieh MT, Sawtell NM. Analysis of herpes simplex virus ICP0 promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo. J Virol. 2003 Nov;77(22):12319-30. Sawtell NM. Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation. J Virol. 2003 Apr;77(7):4127-38.
Sawtell NM, Thompson RL, Stanberry LR, Bernstein DI. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis. 2001 Oct 15;184(8):964-71.
Mary Allen Staat, MD, MPH Director, International Adoption Center 513-636-2877 email@example.com
Director, International Adoption Center
Helicobacter pylori, rotavirus epidemiology, travel medicine and infectious diseases of international adoptees
Epidemiology of enteric infections and surveillance of infectious diseases
Mary Allen Staat, MD, MPH, is director of the International Adoption Center and a member of the Infectious Disease Division at Cincinnati Children's Hospital Medical Center.
Dr. Staat is a board-certified pediatrician and is also board-certified in Infectious Disease and Preventive Medicine. She is an associate professor of Pediatrics at the University of Cincinnati and a faculty member of the Cincinnati Children's Hospital Research Foundation.
MD: University of Kentucky, Lexington, Ky., 1986.
MPH: Johns Hopkins University, Baltimore, Md., 1991.
Residency: Pediatrics, Baylor College of Medicine, Houston, Texas, 1986-1989; Preventive Medicine, Johns Hopkins University, Baltimore, Md., 1990-1994.
Fellowship: Infectious Diseases, Baylor College of Medicine, Houston, Texas, 1989-1990; Epidemiology, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rockville, Md., 1990-1993.
Certification: Pediatrics, 1989; Preventive Medicine, 1996; Pediatric Infectious Diseases, 1999.
Staat MA, Rice MA, Donauer S, Payne DC, Bresee JS, Mast TC, Curns AT, Cortese MM, Connelly B, McNeal M, Ward RL, Bernstein DI, Parashar UD, Salisbury S. Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J. 2010 Dec;29(12):1083-6.
Abdulla RY, Rice MA, Donauer S, Hicks KR, Poore D, Staat MA. Hepatitis A in internationally adopted children: screening for acute and previous infections. Pediatrics. 2010 Nov;126(5):e1039-44.
Staat MA, Stadler LP, Donauer S, Trehan I, Rice M, Salisbury S. Serologic testing to verify the immune status of internationally adopted children against vaccine preventable diseases. Vaccine. 2010 Nov 23;28(50):7947-55.
Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, Poehling K, Weinberg GA, Griffin MR, Hall CB, Finelli L, Bridges C, Staat MA; New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine. 2010 Jul 12;28(31):4913-9.
Mast TC, Walter EB, Bulotsky M, Khawaja SS, DiStefano DJ, Sandquist MK, Straus WL, Staat MA. Burden of childhood rotavirus disease on health systems in the United States. Pediatr Infect Dis J. 2010 Feb;29(2):e19-25. Payne DC, Szilagyi PG, Staat MA, Edwards KM, Gentsch JR, Weinberg GA, Hall CB, Curns AT, Clayton H, Griffin MR, Fairbrother G, Parashar UD. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J. 2009 Nov;28(11):948-53. Dickey M, Jamison L, Michaud L, Care M, Bernstein DI, Staat MA. Rotavirus meningoencephalitis in a previously healthy child and a review of the literature. Pediatr Infect Dis J. 2009 Apr;28(4):318-21.
Linam WM, Margolis PA, Staat MA, Britto MT, Hornung R, Cassedy A, Connelly BL. Risk factors associated with surgical site infection after pediatric posterior spinal fusion procedure. Infect Control Hosp Epidemiol. 2009 Feb;30(2):109-16. Stadler LP, Mezoff AG, Staat MA. Hepatitis B virus screening for internationally adopted children. Pediatrics. 2008 Dec;122(6):1223-8.
Yee EL, Staat MA, Azimi P, Bernstein DI, Ward RL, Schubert C, Matson DO, Turcios-Ruiz RM, Parashar U, Widdowson MA, Glass RI. Burden of rotavirus disease among children visiting pediatric emergency departments in Cincinnati, Ohio, and Oakland, California, in 1999-2000. Pediatrics. 2008 Nov;122(5):971-7.
Mark C. Steinhoff, MD Director, Global Health Center 513-636-1376 firstname.lastname@example.org
Director, Global Health Center
MD: University of Chicago, Chicago, Illinois, 1973.
Residency and Chief Residency: Pediatrics, University of Rochester Medical Center, Rochester, New York.
Fellowship, Infectious Diseases: University of Rochester Medical Center, Rochester, New York.
Certification: New York State Medical License, 1976; Pediatrics, 1978; Tamil Nadu Medical Council (India), 1980; Michigan Medical License, 1985; Maryland Medical License, 1986; Ohio Medical License, 2010; Pediatric Infectious Diseases Society, 1988.
Steinhoff MC, MacDonald N, Pfeifer D, Muglia LJ. Influenza vaccine in pregnancy: policy and research strategies. Lancet. 2014;383:1611-3.
Schlaudecker EP, Steinhoff MC, Omer SB, et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. PLoS one. 2013;8:e70867.
Henkle E, Steinhoff MC, Omer SB, et al. The effect of exclusive breast-feeding on respiratory illness in young infants in a maternal immunization trial in Bangladesh. Pediatr Infect Dis J. 2013;32:431-5.
Zhang T, Zhu Q, Zhang X, et al. The clinical characteristics and direct medical cost of influenza in hospitalized children: a five-year retrospective study in Suzhou, China. PLoS one. 2012;7:e44391.
Steinhoff MC, Omer SB, Roy E, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ. 2012;184:645-53.
Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC. Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis. 2012;206:1670-3.
Omer SB, Goodman D, Steinhoff MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med. 2011;8:e1000441.
Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy--antibody responses in mothers and infants. N Engl J Med. 2010;362:1644-6.
Verghese VP, Friberg IK, Cherian T, et al. Community effect of Haemophilus influenzae type b vaccination in India. Pediatr Infect Dis J. 2009;28:738-40.
Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555-64.
Ming Tan, PhD 513-636-0510 email@example.com
Assistant Professor, UC Department of Pediatrics
Noroviruses; human caliciviruses; viral gastroenteritis
Chen YT, Tan M, Xia M, Hao N, Zhang XJ, Huang PW, Jiang X, Li XM, Rao ZH. Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity selected by human histo-blood group antigen receptors. PLoS Pathogens. 2011.
Tan M, Jiang X. Norovirus-host interaction: multi-selections by the human histo-blood group antigens. Trends in Microbiology. 2011.Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology. 2011 Feb 20;410(2):345-52.
Yang Y, Xia M, Tan M, Huang PW, Zhong WM, Pang XL, Lee BE, Meller J, Wang T, and Jiang X. Genetic and phenotypic characterization of GII-4 noroviruses isolated in 1987-2008. Journal of Virology. 2010 Sep; 84(18): 9595-607. Tan M, and Jiang X. Norovirus gastroenteritis, carbohydrate receptors and animal models. PLoS Pathogen. 2010 Aug 26;6(8). Tan M, Xia M, Chen Y, Bu W, Hegde RS, Meller J, Li X and Jiang X. Conservation of Receptor Binding Interfaces, Evidence of Human HBGA selection in Norovirus Evolution . PLoS One. 2009; 4(4): e5058. Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W and Jiang X. Noroviral P Particle: Structure, Function and Applications in Virus-Host Interaction . Virology. 2008; 382 (1):115-123. Jin M, Xie HP, Duan ZJ, Liu N, Zhang Q, Wu BS, Li HY, Cheng WX, Yang SH, Yu JM, Xu ZQ, Cui SX, Zhu L, Tan M, Jiang X and Fang ZY. Emergence of the GII4/2006b Variant and Recombinant Noroviruses in China . Journal of Medical Virology. 2008; 80(11):1997-2004. Tan M, Xia M, Cao S, Huang P, Farkas T, Meller J, Hegde RS, Li X, Rao Z and Jiang X. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study . Virology. 2008; 379(2):324-334.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center